AstraZeneca’s (AZN) Hold Rating Reiterated at Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN)‘s stock had its “hold” rating reissued by equities researchers at Deutsche Bank Aktiengesellschaft in a research note issued to investors on Tuesday, Digital Look reports. They currently have a £105 ($129.69) price target on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price target indicates a potential downside of 6.81% from the stock’s current price.

Several other equities research analysts have also recently issued reports on the stock. Jefferies Financial Group restated a “hold” rating and set a £110 ($135.87) price objective on shares of AstraZeneca in a research report on Friday, February 16th. UBS Group dropped their price objective on shares of AstraZeneca from £107 ($132.16) to GBX 9,900 ($122.28) and set a “sell” rating for the company in a report on Monday, February 12th. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research note on Thursday, April 4th. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research note on Monday, April 15th. Finally, BMO Capital Markets restated an “outperform” rating on shares of AstraZeneca in a research report on Monday, February 12th. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, AstraZeneca presently has an average rating of “Moderate Buy” and an average target price of £116.86 ($144.34).

AstraZeneca Price Performance

AZN traded up GBX 16.78 ($0.21) during midday trading on Tuesday, hitting £112.67 ($139.16). 3,278,211 shares of the company traded hands, compared to its average volume of 2,195,781. The company has a current ratio of 0.82, a quick ratio of 0.59 and a debt-to-equity ratio of 75.70. The company has a market capitalization of £174.64 billion, a price-to-earnings ratio of 3,718.41, a PEG ratio of 0.89 and a beta of 0.19. AstraZeneca has a 52-week low of GBX 9,461 ($116.86) and a 52-week high of £123.48 ($152.52). The business has a 50 day simple moving average of £104.30 and a two-hundred day simple moving average of £104.25.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.